tebentafusp (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Uveal Melanoma

Pending FDA approval for treatment of HLA-A*02:01-positive metastatic uveal melanoma (mUM)

Next:

Pharmacology

Mechanism of Action

Bispecific protein comprised of a soluble T-cell receptor fused to an anti-CD3 immune-effector function that specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma

Immune-mobilizing monoclonal T-cell receptors (TCRs) against cancer (ImmTAC) molecules bind cells that present a peptide derived from an antigen of interest, and recruit T-cells to lyse the target cells; to achieve this, ImmTAC molecules are composed of a TCR targeting domain and a single-chain variable fragment (scFv) anti-CD3 effector domain

The TCR targeting domain binds peptides presented on the cell surface as a human leukocyte antigen (HLA)-peptide (pHLA) complex, while the anti-CD3 effector domain engages and activates CD3+ cells

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.